S&P 500
7,757.17
+44.60
+0.58%
Dow
52,856.09
+360.19
+0.69%
Nasdaq
26,702.86
+278.04
+1.05%
NYSE Composite
24,253.12
+62.52
+0.26%
Russell 2000
2,781.02
+7.60
+0.27%
VIX
16.68
-0.63
-3.64%
QNCX · Quince Therapeutics, Inc.
NASDAQ NMS - GLOBAL MARKET - BOATS Real Time Price • USD
Quince Therapeutics Inc (QNCX)
NASDAQ NMS - GLOBAL MARKET
Biotechnology
$31.14
+1.85
(+6.30%)
● At close: October 9 at 4:00:00 PM EDT
DAY'S RANGE
$31.14
$30.65
$36.26
52-WEEK RANGE
$31.14
$15.10
$910.00
What's happening
- QNCX is up 6.30% today, trading at $31.14. — Live quote
- It's trading within 3% of its 52-week low ($15.10). (Finnhub fundamentals)
- Volume today (8,538) is well below its 3-month average of 33,890. (Finnhub fundamentals)
- Reports earnings on 2026-11-10, 19 days away. (Finnhub earnings calendar)
- Last quarter's EPS beat estimates: $-12.31 actual vs. $-18.24 estimated (+32.5%). (Finnhub earnings history)
Deterministic template sentences filled in from the same sourced figures shown elsewhere on this page -- not an AI-written summary, no live model call.
Key Statistics
Analyst Recommendations
Strong buy 4
Buy 8
Hold 1
Sell 0
Strong sell 0
Aggregate ratings for 2026-10-01 (13 analysts polled by Finnhub) — consensus count.
Performance Overview (Trailing returns vs S&P 500 benchmark)
YTD RETURN
QNCX
-93.99%
vs S&P 500
-106.77%
1-YEAR RETURN
QNCX
-89.12%
vs S&P 500
-103.68%
6-MONTH RETURN
QNCX
+50.26%
3-MONTH RETURN
QNCX
+114.43%
Earnings Trends (Quarterly EPS Actual vs Estimate)
2026-07-26 (Q2 2026)
$-12.31
Est. $-18.24
BEAT +32.5%
2026-04-26 (Q1 2026)
$57.60
Est. $-52.22
BEAT +210.3%
2026-01-26 (Q4 2025)
$-142.00
Est. $-38.52
MISS -268.7%
2025-10-26 (Q3 2025)
$-50.00
Est. $-44.15
MISS -13.3%
Valuation Measures & Ratios
Enterprise Value4-$83.7M
Forward P/E5—
PEG Ratio6—
Price / Sales (TTM1)—
Price / Book70.16
EV4 / Revenue—
EV4 / EBITDA—
Profit Margin—
Operating Margin—
Return on Equity (ROE8)-127.02%
Return on Assets (ROA9)-104.48%
Avg Volume (3M)33,890
Quarterly history (5 periods)
| Measure | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 |
|---|---|---|---|---|---|
| Market cap | $107.2M | $16.3M | $1.17B | $5.1M | $77.3M |
| P/E | -1.55 | -1.90 | -23.36 | -0.08 | -1.30 |
| Price/Book | -3.04 | 1.04 | 1103.28 | 0.44 | 4.16 |
| ROE | 195.52% | -54.93% | -4722.66% | -547.89% | -319.68% |
| ROA | -55.70% | -32.34% | -45.51% | -54.86% | -55.47% |
Trailing-twelve-month ratios computed from SEC EDGAR quarterly figures and historical daily close prices (Alpaca). Diluted shares are derived from Net income ÷ EPS (diluted) for each quarter, not separately reported. Forward P/E/PEG unavailable (no free data source).
Glossary — what these abbreviations mean
- 1. TTM
- Trailing twelve months — the sum of the last four reported quarters, not a calendar year or the single latest quarter.
- 2. EPS
- Earnings per share — net income divided by diluted shares outstanding.
- 3. Beta
- A stock's historical volatility relative to the overall market. Above 1 means it has moved more than the market; below 1, less.
- 4. EV (Enterprise Value)
- Market cap plus total debt minus cash — roughly what it would cost to buy the whole company, debt included.
- 5. Forward P/E
- Price divided by analysts' estimated earnings for the next 12 months, instead of trailing actual earnings.
- 6. PEG Ratio
- P/E divided by expected earnings growth rate. A lower number can indicate a stock is cheap relative to how fast it's expected to grow.
- 7. Price / Book
- Share price divided by book value (assets minus liabilities) per share.
- 8. ROE
- Return on equity — net income divided by shareholders' equity, a measure of how efficiently a company turns equity into profit.
- 9. ROA
- Return on assets — net income divided by total assets, a measure of how efficiently a company turns assets into profit.
- 10. MRQ
- Most recent quarter — the single latest reported period, as opposed to TTM. The Financials section's "Quarterly" view below shows MRQ-style figures.
- 11. YoY
- Year over year — percent change versus the same period one year earlier, used for growth figures like those on Compare cards and the Screener.
Short Interest
Shares Short59,944
Change from Prior Settlement+19.24%
% of Float—
Days to Cover (Short Ratio)2.67
Source: FINRA Rule 4560 consolidated short interest, settlement date 2026-09-30. Reported bi-monthly with a reporting lag — not real-time.
Quotes and the 1-day extended-hours chart: Yahoo Finance. Longer historical charts: Alpaca (IEX feed) — real-time but IEX-only volume (~2.5% of consolidated market volume). Fundamentals + earnings: Finnhub.
Price history
Events
Drag horizontally to zoom into a section; use Reset view to restore all observations.
Technical signal summary
Calculating from the latest year of daily price history…
Show Technical Analysis Breakdown ▾ 10 Indicators
Not investment advice — read several signals together.
Indicators None active
Loading chart…
History limited by data provider; markers are heuristics, not signals.
Peer and sector context
No reviewed peer group is available for this symbol.
Balanced evidence
A deterministic summary of sourced facts—not an AI verdict.
Potential strengths
- Latest SEC filing is Form 8-K, filed 2026-10-19; review it for current changes and risks. SEC EDGAR ↗
Potential concerns
- Trailing 52-week price return is -89.1%. Finnhub market metrics ↗
Rule-based facts only; absence from either side is not evidence, and this is not a recommendation.
More on QNCX
No accessible free API for these — links go to the source directly.
Financials
Fundamental trends
Visualized from the same SEC figures in the tables below.
Income statement
| Line item | Jun '26 | Mar '26 | Sep '25 | Jun '25 | Mar '25 | Sep '24 | Jun '24 | Mar '24 |
|---|---|---|---|---|---|---|---|---|
| Operating income | -$79.8M | -$14.6M | -$13.4M | -$10.4M | -$14.9M | -$5.9M | -$28.2M | -$11.2M |
| Net income | -$75.5M | $35.9M | -$13.4M | -$16.0M | -$15.0M | -$5.5M | -$27.7M | -$11.1M |
| EPS (diluted) | $-12.31 | $2.88 | $-0.25 | $-68.75 | $-3.42 | $-0.13 | $-0.64 | $-0.26 |
| EPS (basic) | $-12.31 | $3.60 | $-0.25 | $-68.75 | $-3.42 | $-0.13 | $-0.64 | $-0.26 |
Balance sheet
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Total assets | $124.0M | $26.6M | $93.5M | $109.9M | $117.2M | $107.1M | $114.5M | $126.5M |
| Total liabilities | $15.5M | $11.0M | $129.2M | $108.8M | $105.5M | $88.5M | $84.3M | $81.6M |
| Stockholders' equity | -$35.3M | $15.7M | -$35.7M | $1.1M | $11.7M | $18.6M | $30.1M | $44.9M |
| Total current assets | $123.4M | $25.6M | $22.9M | $29.2M | $37.3M | $33.8M | $44.0M | $51.7M |
| Total current liabilities | $8.5M | $8.8M | $43.2M | $26.0M | $7.5M | $8.4M | $7.3M | $5.4M |
| Cash & equivalents | $116.0M | $18.2M | $5.8M | $6.5M | $16.8M | $7.8M | $6.2M | — |
| Marketable securities (current) | $0 | $0 | $11.9M | — | — | — | — | — |
| Accounts receivable | — | — | — | — | — | — | — | — |
| Other current assets | $393.0K | $24.0K | $54.0K | $96.0K | $55.0K | $32.0K | $84.0K | $55.0K |
| Property, plant & equipment | $506.0K | $550.0K | $595.0K | $616.0K | $573.0K | $448.0K | $315.0K | $208.0K |
| Goodwill | — | — | — | $0 | — | — | $0 | $0 |
| Intangible assets | $0 | $0 | $67.8M | $67.7M | $67.6M | $62.4M | $60.0M | $64.5M |
| Other non-current assets | $78.0K | $78.0K | $1.8M | $11.9M | $11.2M | $10.0M | $9.6M | $9.5M |
| Accounts payable | $4.6M | $5.4M | $2.2M | $3.4M | $1.8M | $3.0M | $2.9M | $1.6M |
| Accrued liabilities | $3.9M | $3.4M | $10.6M | $5.1M | $5.7M | $5.3M | $4.4M | $3.8M |
| Short-term debt | $0 | $0 | $18.0M | $17.5M | — | — | $0 | — |
| Long-term debt | — | — | $0 | $0 | $17.0M | $15.3M | $14.3M | $14.9M |
| Other non-current liabilities | $716.0K | $1.2M | $1.6M | $778.0K | $745.0K | $716.0K | $685.0K | $643.0K |
| Common stock & paid-in capital | $1.0K | $14.0K | $0 | $54.0K | $53.0K | $44.0K | $44.0K | $43.0K |
| Retained earnings | -$500.0M | -$424.5M | -$460.5M | -$421.0M | -$407.6M | -$391.5M | -$376.5M | -$364.0M |
| Accumulated other comprehensive income (loss) | $4.3M | $4.6M | $5.8M | $6.3M | $6.2M | $2.0M | -$35.0K | $3.4M |
Cash flow
| Line item | Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 |
|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$18.9M | -$7.6M | -$10.5M | -$9.9M | -$11.4M | -$9.6M | -$7.6M | -$7.3M |
| Investing cash flow | $8.0M | $12.0M | $8.1M | -$1.8M | $6.0M | $10.9M | $10.9M | $7.1M |
| Financing cash flow | $108.9M | $9.4M | $2.0M | $1.4M | $14.4M | $87.0K | $0 | -$5.0M |
| Free cash flow | -$18.9M | -$7.6M | -$10.5M | -$10.0M | -$11.5M | -$9.7M | -$7.7M | -$7.3M |
| Capital expenditures | $0 | $0 | $4.0K | $74.0K | $126.0K | $148.0K | $133.0K | $46.0K |
| Share-based compensation | $12.1M | $1.3M | $1.2M | $1.3M | $1.3M | $1.4M | $1.1M | $1.1M |
| Deferred income taxes | — | — | -$5.6M | — | — | — | -$45.0K | — |
| Change in accounts payable | $260.0K | $5.9M | -$1.2M | $1.6M | -$1.4M | $22.0K | $1.4M | -$825.0K |
| Purchases of investments | $0 | $0 | $4.9M | $15.7M | $11.8M | $2.0M | $0 | $3.8M |
Income statement
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating income | -$58.1M | -$57.3M | -$34.6M | -$52.0M | -$90.3M |
| Net income | -$84.0M | -$56.8M | -$31.4M | -$51.7M | -$89.9M |
| EPS (diluted) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 |
| EPS (basic) | $-1.68 | $-1.31 | $-0.84 | $-1.54 | $-3.03 |
Balance sheet
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | May '22 |
|---|---|---|---|---|---|
| Total assets | $93.5M | $114.5M | $167.9M | $103.9M | — |
| Total liabilities | $129.2M | $84.3M | $82.8M | $3.3M | — |
| Stockholders' equity | -$35.7M | $30.1M | $85.1M | $100.6M | — |
| Total current assets | $22.9M | $44.0M | $77.4M | $93.7M | — |
| Total current liabilities | $43.2M | $7.3M | $9.6M | $3.1M | — |
| Cash & equivalents | $5.8M | $6.2M | — | — | — |
| Other current assets | $54.0K | $84.0K | $81.0K | $276.0K | — |
| Property, plant & equipment | $595.0K | $315.0K | $234.0K | $393.0K | — |
| Goodwill | — | $0 | $17.6M | $0 | $825.0K |
| Intangible assets | $67.8M | $60.0M | $63.7M | $5.9M | — |
| Other non-current assets | $1.8M | $9.6M | $8.5M | $0 | — |
| Accounts payable | $2.2M | $2.9M | $2.0M | $570.0K | — |
| Accrued liabilities | $10.6M | $4.4M | $3.4M | $2.5M | — |
| Short-term debt | $18.0M | $0 | — | — | — |
| Long-term debt | $0 | $14.3M | $13.4M | $0 | — |
| Other non-current liabilities | $1.6M | $685.0K | $587.0K | $0 | — |
| Common stock & paid-in capital | $55.0K | $44.0K | $43.0K | $36.0K | — |
| Retained earnings | -$460.5M | -$376.5M | -$319.6M | -$288.3M | — |
| Accumulated other comprehensive income (loss) | $5.8M | -$35.0K | $3.0M | -$289.0K | — |
Cash flow
| Line item | Dec '25 | Dec '24 | Dec '23 | Dec '22 | Dec '21 |
|---|---|---|---|---|---|
| Operating cash flow | -$41.4M | -$31.9M | -$18.3M | -$44.0M | -$62.9M |
| Investing cash flow | $23.2M | $21.9M | -$5.8M | $18.0M | $59.0M |
| Financing cash flow | $17.9M | -$4.8M | $143.0K | $707.0K | $6.8M |
| Free cash flow | -$41.8M | -$32.2M | -$18.5M | -$44.2M | -$63.1M |
| Capital expenditures | $352.0K | $257.0K | $160.0K | $133.0K | $180.0K |
| Share-based compensation | $5.1M | $4.7M | $5.2M | $16.6M | $29.9M |
| Deferred income taxes | -$5.6M | -$45.0K | -$258.0K | $284.0K | — |
| Change in accounts payable | -$940.0K | $927.0K | -$288.0K | -$5.9M | $1.4M |
| Purchases of investments | $34.4M | $89.6M | $113.8M | — | — |
Source: SEC EDGAR XBRL filings (10-Q/10-K), as originally tagged by the company. Quarterly cash flow is reconstructed by de-cumulating fiscal-year-to-date figures (how cash flow is tagged in 10-Qs); other quarterly lines are reported directly.
Institutional holders
SEC Form 13F filers holding QNCX as of the latest reported quarter. 13F only covers investment managers with $100M+ in assets — this is not a complete ownership picture, and does not include insiders (see Recent SEC filings below) or non-13F-eligible holders.
Institutional ownership is not available for this symbol right now.
Insider activity
Directors, officers, and 10%+ owners' reported transactions from SEC Form 4. A filing reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR Form 4 filings · checked 25 most recent filings · covers 2024-10-23 to 2025-12-26
Recent transactions
- Most recent: Benatti Luca (Reporting person) — Open market sale of 50,000 shares on 2025-12-26.
Deterministic template sentences filled in from the SEC Form 4 figures in the tables below -- not an AI-written summary, no live model call.
Insider purchases & sales, last 6 months
Purchases (open market)0 sh(0 txns)
Sales (open market)0 sh(0 txns)
Net Shares+0
Counts only open-market purchases (code P) and sales (code S) — grants, option exercises, tax withholding, and gifts are excluded since they aren't a market buy/sell decision.
Insider roster
| Name | Title | Most Recent Transaction | Date | Shares |
|---|---|---|---|---|
| Benatti Luca | Reporting person | Open market sale | 2025-12-26 | 50,000 |
| Thye Dirk | CEO and CMO | Gift | 2025-12-10 | 739,885 |
| Hannah Brendan | CBO, COO & CCO | Option exercise | 2025-12-05 | 2,271 |
| Ryan Charles S. | President | Grant / award | 2025-06-18 | 7,548 |
Recent transactions
| Date | Insider | Title | Transaction | Shares | Price |
|---|---|---|---|---|---|
| 2025-12-26 | Benatti Luca | Reporting person | Open market sale | 50,000 | $3.47 |
| 2025-12-10 | Thye Dirk | CEO and CMO | Gift | 739,885 | $0.00 |
| 2025-12-10 | Thye Dirk | CEO and CMO | Gift | 739,885 | $0.00 |
| 2025-12-05 | Hannah Brendan | CBO, COO & CCO | Option exercise | 2,271 | $0.55 |
| 2025-12-05 | Hannah Brendan | CBO, COO & CCO | Option exercise | 25,280 | $0.94 |
| 2025-06-18 | Hannah Brendan | CBO, COO & CCO | Grant / award | 37,736 | $1.20 |
| 2025-06-18 | Ryan Charles S. | President | Grant / award | 7,548 | $1.20 |
| 2025-06-18 | Thye Dirk | CEO and CMO | Grant / award | 150,944 | $1.20 |
| 2024-10-23 | Benatti Luca | Reporting person | Other acquisition/disposition | 8,918 | — |
Recent SEC filings
Official company reports and insider transaction filings. Form 4 reports a transaction; it does not by itself explain why it happened.
Source: SEC EDGAR submissions · updated 2026-10-22 06:16 UTC
| Filed | Form | Report period | Official filing |
|---|---|---|---|
| 2026-10-19 | 8-K | 2026-10-19 | View on SEC.gov → |
| 2026-10-09 | 8-K | 2026-10-07 | View on SEC.gov → |
| 2026-10-06 | 8-K | 2026-10-06 | View on SEC.gov → |
| 2026-10-02 | 8-K | 2026-09-30 | View on SEC.gov → |
| 2026-09-14 | 8-K | 2026-09-08 | View on SEC.gov → |
| 2026-09-04 | 8-K | 2026-08-31 | View on SEC.gov → |
| 2026-08-27 | 8-K | 2026-08-23 | View on SEC.gov → |
| 2026-08-17 | 8-K | 2026-08-17 | View on SEC.gov → |
| 2026-08-14 | 10-Q | 2026-06-30 | View on SEC.gov → |
| 2026-08-14 | 8-K | 2026-08-14 | View on SEC.gov → |
| 2026-07-31 | 8-K | 2026-07-29 | View on SEC.gov → |
| 2026-06-26 | 8-K | 2026-06-26 | View on SEC.gov → |
Recent news
Headlines about QNCX (Quince Therapeutics, Inc.). Links open the publisher — we don’t host full articles.
-
Quince Therapeutics (IRLA) 10K Form and Latest SEC Filings 2026
MarketBeat · 2026-10-19 -
IRulya schedules October 22 conference: ticker for Quince Therapeutics stock changes to IRLA - ad-hoc-news.de
ad-hoc-news.de · 2026-10-15 -
Quince Therapeutics Renames as IRulya Therapeutics, Advances Pulmonary Drug Development
Yahoo · 2026-10-09 -
Quince Therapeutics Relaunches as IRulya Therapeutics with a Focus on the Clinical Development of LAM-001, Targeting a Key Pathway in Pulmonary Disease
Yahoo · 2026-10-09 -
Raymond James Initiates Coverage On Quince Therapeutics with Outperform Rating, Announces Price Target of $72
Benzinga · 2026-10-09 -
CoreWeave upgraded, Etsy downgraded: Wall Street's top analyst calls
Yahoo Finance · 2026-09-24 -
Netflix downgraded, SanDisk initiated: Wall Street's top analyst calls
Yahoo Finance · 2026-09-22 -
Quince Therapeutics to Host Virtual KOL Event to Discuss the Current Treatment Landscape for PH-ILD and BOS and the Role for LAM-001 as a Potential Therapeutic Option on September 28, 2026
Yahoo Finance · 2026-09-17
No headlines in this category right now — try “All”.